Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
1.
Int J Radiat Oncol Biol Phys ; 74(4): 1012-7, 2009 Jul 15.
Article in English | MEDLINE | ID: mdl-19117697

ABSTRACT

PURPOSE: We discuss our experiences with fractionated stereotactic radiotherapy (FSR) in the treatment of cavernous sinus meningiomas. METHODS AND MATERIALS: From 1995 to 2006, we monitored 100 patients diagnosed with cavernous sinus meningiomas; 84 female and 16 male patients were included. The mean patient age was 56 years. The most common symptoms were a reduction in visual acuity (57%), diplopia (50%), exophthalmy (30%), and trigeminal neuralgia (34%). Surgery was initially performed on 26 patients. All patients were treated with FSR. A total of 45 Gy was administered to the lesion, with 5 fractions of 1.8 Gy completed each week. Patient treatment was performed using a Varian Clinac linear accelerator used for cranial treatments and a micro-multileaf collimator. RESULTS: No side effects were reported. Mean follow-up period was 33 months, with 20% of patients undergoing follow-up evaluation of more than 4 years later. The tumor control rate at 3 years was 94%. Three patients required microsurgical intervention because FSR proved ineffective. In terms of functional symptoms, an 81% improvement was observed in patients suffering from exophthalmy, with 46% of these patients being restored to full health. A 52% improvement was observed in diplopia, together with a 67% improvement in visual acuity and a 50% improvement in type V neuropathy. CONCLUSIONS: FSR facilitates tumor control, either as an initial treatment option or in combination with microsurgery. In addition to being a safe procedure with few side effects, FSR offers the significant benefit of superior functional outcomes.


Subject(s)
Cavernous Sinus , Meningeal Neoplasms/surgery , Meningioma/surgery , Radiosurgery/methods , Adult , Aged , Female , Follow-Up Studies , Humans , Magnetic Resonance Imaging , Male , Meningeal Neoplasms/complications , Meningeal Neoplasms/pathology , Meningioma/complications , Meningioma/pathology , Middle Aged , Treatment Outcome , Tumor Burden
2.
J Forensic Sci ; 53(2): 499-502, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18366586

ABSTRACT

Thiodicarb is a nonsystemic carbamate insecticide whose acetylcholinesterase activity is related to its main methomyl degradation product. A 40-year-old woman was found dead in her car. Empty packages of medicines and an open bottle of Larvin containing thiodicarb were found near her body. No signs of violence nor traumatic injuries were noticed upon autopsy, and police investigations strongly suggested a suicide. Systematic toxicological analysis performed on postmortem specimens revealed the presence of various sedatives, hypnotics, and antipsychotic drugs in blood, urine, and gastric content. Some of the compounds identified were determined at blood concentrations well above the known therapeutic concentrations: zolpidem (2.87 mg/L), bromazepam (2.39 mg/L), nordazepam (4.21 mg/L), and levopremazine (0.64 mg/L). Specific analysis of thiodicarb and of its methomyl metabolite was then performed on all fluids and tissues collected during autopsy by liquid chromatography ion trap tandem mass spectrometry (LC-MS-MS). The anticholinesterase capacity of blood, urine, and gastric content collected at autopsy was 83%, 82%, and 32%, respectively (normal value: 0%). The presence of thiodicarb in the bottle found near the body corroborates the hypothesis of an intake of that compound. Although thiodicarb was only detected in gastric content (24.3 mg/L), its methomyl metabolite was quantified in most postmortem tissues and fluids: gastric content (19.9 mg/L), peripheral blood (0.7 mg/L), urine (8.5 mg/L), bile (2.7 mg/L), liver (0.7 mg/kg), kidney (1.7 mg/kg), lung (1.5 mg/kg), brain (9.3 mg/kg), and heart (3.6 mg/kg).


Subject(s)
Insecticides/pharmacokinetics , Insecticides/poisoning , Methomyl/pharmacokinetics , Methomyl/poisoning , Thiocarbamates/pharmacokinetics , Thiocarbamates/poisoning , Adult , Bile/chemistry , Body Fluids/chemistry , Brain Chemistry , Female , Forensic Toxicology , Gastrointestinal Contents/chemistry , Humans , Kidney/chemistry , Liver/chemistry , Lung/chemistry , Myocardium/chemistry , Tissue Distribution
3.
J Clin Endocrinol Metab ; 88(3): 998-1001, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12629075

ABSTRACT

The mechanisms of adrenocortical tumorigenesis are still not fully understood. Data from clonal analysis, comparative genomic hybridization, and allelotyping suggest that it involves a multistep process during which several genetic defects are progressively acquired, leading to the malignant transformation. The events involved in the first steps of this process are not well known, and most of the abnormalities described in adrenocortical tumors to date are associated with the malignant phenotype. We report a case that suggests that adrenocortical tumorigenesis may be a multistep process. A 43-yr-old patient underwent surgery for an incidentally discovered adrenal mass. Pathological analysis showed that this tumor consisted of two parts: a central part with features of malignancy surrounded by another part with a strictly benign appearance. These data were confirmed by molecular analysis and comparative genomic hybridization that were consistent with either a malignant or benign presentation. The apparently malignant part of the tumor exhibited molecular abnormalities [17p13 loss of heterozygosity (LOH), 11p15 uniparental disomy and overexpression of the IGF-II gene] as well as chromosomal gains and losses (comparative genomic hybridization) that have been previously described in malignant tumors. No abnormalities were found in the surrounding benign tissues. Although this observation is not definitive proof that adrenocortical tumorigenesis occurs via a multistep process, it suggests that there is a progressive change from the benign to the malignant state in some adrenocortical tumors.


Subject(s)
Adrenal Cortex Neoplasms/etiology , Adrenal Cortex Neoplasms/genetics , Adrenal Cortex Neoplasms/pathology , DNA, Neoplasm/analysis , Humans , Insulin-Like Growth Factor II/genetics , Loss of Heterozygosity , Male , Middle Aged , Nucleic Acid Hybridization
4.
Am J Surg Pathol ; 26(8): 1007-15, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12170087

ABSTRACT

Distant metastases (DM) are rare in well-differentiated thyroid carcinomas and correlate with a poor survival. Among the histologic subtypes, insular carcinoma has an intermediate prognosis that lies between well and undifferentiated carcinomas. To assess the characteristics that could predict a worse prognosis, we reviewed the initial thyroid cancer slides from patients with DM. We achieved a comparative statistical analysis with a control group without DM. Among 1230 differentiated carcinomas treated from 1960 to 1999, 9% developed DM. In this group the mean age was 53 years, with a 73% rate of death. The histologic slides were available in 80 cases. The primary thyroid tumors were classified as papillary (51 cases), follicular (25), and pure insular carcinomas (4). Extrathyroidal extension was present in 47% of papillary carcinomas. The mean tumor size was above 5 cm for all the histologic subtypes, and at least a vascular invasion was found in 69%. Fifty-four percent of these tumors had an insular component compared with only 6.5% in the control group. The statistical analysis confirmed by univariate and multivariate logistic regression that the risk of DM was highly elevated in the presence of insular carcinoma. Our study indicates that elevated age, large tumor size, vascular invasion, and extrathyroidal extension are important prognostic factors in well-differentiated carcinomas. We also demonstrate that the presence of an insular component in an otherwise differentiated carcinoma is a strong independent poor prognostic factor.


Subject(s)
Carcinoma/pathology , Thyroid Neoplasms/pathology , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Carcinoma/mortality , Carcinoma, Papillary/mortality , Carcinoma, Papillary/pathology , Female , Humans , Immunohistochemistry , Male , Middle Aged , Prognosis , Regression Analysis , Sex Factors , Thyroid Neoplasms/mortality
SELECTION OF CITATIONS
SEARCH DETAIL